Filing Details
- Accession Number:
- 0001385508-19-000035
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-03 16:08:50
- Reporting Period:
- 2019-04-01
- Accepted Time:
- 2019-04-03 16:08:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1385508 | Opiant Pharmaceuticals Inc. | OPNT | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1358116 | Phil Skolnick | C/O Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd., Suite 500 Santa Monica CA 90401 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-01 | 10,000 | $9.00 | 10,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-04-01 | 7,993 | $12.71 | 2,007 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-04-02 | 2,007 | $12.47 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-04-01 | 10,000 | $0.00 | 10,000 | $9.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 130,000 | 2018-08-06 | 2027-02-06 | No | 4 | M | Direct |
Footnotes
- The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- This transaction was executed in multiple trades at prices ranging from $12.50 to $13.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
